Core Insights - CVS Group reported continued progress in providing care to animals during the interim results for the six-month period ending December 2025 [2] - The company completed its transition from AIM to the main market on January 29, 2026, aiming for improved liquidity and access to a diverse pool of capital [2] Company Developments - A new consumer-facing U.K. companion animal joint brand under CVS Vets has been launched, reflecting the company's commitment to care, value, and service [3] - CVS Group's presence in Australia is expanding, with three acquisitions completed in the reporting period and two additional practice acquisitions in the second half of the year [3] - The company has maintained disciplined capital investment to enhance facilities, clinical equipment, and technology, which is expected to drive long-term growth in shareholder value [3] Industry Engagement - CVS Group welcomes the launch of a consultation by DEFRA regarding the Veterinary Surgeons Act from 1966 and is actively engaging in the process [4] - The company is anticipating the final decision from the CMA in the coming weeks [4]

Core Viewpoint - CVS Group plans to move its listing from the Alternative Investment Market to the London Stock Exchange's Main Market, indicating a strategic shift to enhance its visibility and access to capital [1] Group 1: Company Actions - The company has approved a new 20 million pound share buyback program, reflecting confidence in its financial position and commitment to returning value to shareholders [1]

Core Viewpoint - Russian scientists have developed a biodegradable implant with shape memory functionality for treating animal joint injuries, which can accelerate recovery and reduce complications, making veterinary services more convenient [1][2]. Group 1: Implant Features - The implant is designed to fix diseased joints in animals and gradually degrade safely within the body, eliminating the need for secondary surgeries [2]. - The material used in the implant has shape memory properties, allowing it to adapt precisely to the anatomical structure of the affected animal, thus speeding up postoperative recovery and minimizing complications [2][3]. - The implant is made from 3D-printed biodegradable polymers filled with hydroxyapatite and silica, enhancing structural strength and compatibility with bone tissue [2][3]. Group 2: Clinical Implications - The implant serves as an "internal cast," suitable for both small animals, like dogs with comminuted fractures, and large animals with intra-articular fractures, allowing joints to rest [5]. - The combination of biodegradable and shape memory functionalities in the implant is expected to improve the accessibility of joint fixation surgeries [5]. - Future studies will focus on the implant's self-positioning ability, biocompatibility, and effectiveness in live animals [3]. Group 3: Technological Advancements - The use of advanced additive manufacturing techniques and 3D printing in biomedical and bioengineering fields shows significant potential for future developments [5].